Scroll

hyoscyamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
atropine derivatives	1402	101-31-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: hyoscyamine hydrobromide hyoscyamine (-)-Atropine (-)-Hyoscyamine L-Hyoscyamin L-Hyoscyamine l-Atropine hyoscyamine sulfate	The 3(S)-endo isomer of atropine. Molecular weight: 289.38 Formula: C17H23NO3 CLOGP: 1.30 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 49.77 ALOGS: -2.06 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

hyoscyamine hydrobromide
hyoscyamine
(-)-Atropine
(-)-Hyoscyamine
L-Hyoscyamin
L-Hyoscyamine
l-Atropine
hyoscyamine sulfate

The 3(S)-endo isomer of atropine.

Molecular weight: 289.38
Formula: C17H23NO3
CLOGP: 1.30
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 49.77
ALOGS: -2.06
ROTB: 5

Drug dosage:

Dose	Unit	Route
1.20	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	57 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2000 mg/mL	Bocci G, Oprea TI, Benet LZ
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1869	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cholecystitis chronic	146.69	13.78	59	11394	10302	63467267
Biliary dyskinesia	73.71	13.78	25	11428	2704	63474865
Gallbladder disorder	67.06	13.78	42	11411	18800	63458769
Abdominal pain	44.62	13.78	135	11318	293321	63184248
Anticholinergic syndrome	35.21	13.78	14	11439	2368	63475201
Emotional distress	33.39	13.78	35	11418	32514	63445055
Vision blurred	32.54	13.78	59	11394	91865	63385704
Anxiety	30.17	13.78	97	11356	217444	63260125
Drug ineffective	28.78	13.78	95	11358	1044670	62432899
Injury	28.49	13.78	49	11404	73198	63404371

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	27.99	19.77	48	2724	163570	34790589
Faecal calprotectin abnormal	22.84	19.77	5	2767	237	34953922

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cholecystitis chronic	147.46	14.16	53	9917	9853	79724565
Gallbladder disorder	71.93	14.16	39	9931	19301	79715117
Biliary dyskinesia	67.32	14.16	21	9949	2524	79731894
Abdominal pain	37.17	14.16	120	9850	389449	79344969
Anticholinergic syndrome	34.54	14.16	14	9956	3597	79730821
Emotional distress	34.33	14.16	33	9937	39936	79694482
Vision blurred	32.45	14.16	52	9918	105846	79628572
Injury	32.33	14.16	44	9926	77452	79656966
Cholelithiasis	30.10	14.16	35	9935	52629	79681789
Muscle spasms	26.73	14.16	64	9906	174666	79559752

Showing 1 to 10 of 23 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A03BA03	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS BELLADONNA AND DERIVATIVES, PLAIN Belladonna alkaloids, tertiary amines
ATC	A03CB31	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Belladonna and derivatives in combination with psycholeptics
CHEBI has role	CHEBI:76924	plant metabolites
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents

Showing 1 to 10 of 17 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Dysuria	indication	49650001
Sinus bradycardia	indication	49710005
Excessive salivation	indication	53827007
Gastrointestinal Radiography Adjunct	indication
Muscarine Toxicity	indication
Cholinesterase Inhibitors Toxicity	indication
Urinary Tract Irritation	indication
Irritable bowel syndrome	off-label use	10743008	DOID:9778
Diarrhea	off-label use	62315008

Showing 1 to 10 of 105 entries

Previous1 2 3 4 5…11Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.24	acidic
pKa2	9.26	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9	WOMBAT-PK	KEGG DRUG
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	9.30	WOMBAT-PK	KEGG DRUG
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	9.80	WOMBAT-PK	KEGG DRUG
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	9.90	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	9.20	WOMBAT-PK

Showing 1 to 5 of 5 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
001727	NDDF
001728	NDDF
001729	NDDF
1047802	RXNORM
174174	PUBCHEM_CID
20634	MMSL
306-03-6	SECONDARY_CAS_RN
372757002	SNOMEDCT_US
387391003	SNOMEDCT_US
4018398	VANDF

Showing 1 to 10 of 35 entries

Previous1 2 3 4Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ANASPAZ	HUMAN PRESCRIPTION DRUG LABEL	1	0225-0295	TABLET, ORALLY DISINTEGRATING	0.13 mg	SUBLINGUAL	unapproved drug other	21 sections
Belladonna Alkaloids with Phenobartbital	HUMAN PRESCRIPTION DRUG LABEL	4	0440-7183	TABLET	0.10 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
Donnatal	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0423	ELIXIR	0.10 mg	ORAL	unapproved drug other	12 sections
ED-SPAZ	HUMAN PRESCRIPTION DRUG LABEL	1	0485-0082	TABLET, ORALLY DISINTEGRATING	0.13 mg	ORAL	unapproved drug other	20 sections
Hyophen	HUMAN PRESCRIPTION DRUG LABEL	5	0076-0901	TABLET	0.12 mg	ORAL	unapproved drug other	19 sections
Hyoscyamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-442	TABLET	0.13 mg	ORAL	Unapproved drug other	18 sections
Hyosyne	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0511	ELIXIR	0.13 mg	ORAL	unapproved drug other	11 sections
Hyosyne	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0514	ELIXIR	0.13 mg	ORAL	unapproved drug other	11 sections
Levsin	HUMAN PRESCRIPTION DRUG LABEL	1	0037-9001	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	Unapproved drug other	11 sections
Levsin	HUMAN PRESCRIPTION DRUG LABEL	1	0037-9001	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	Unapproved drug other	11 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next